Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Gyre Therapeutics is a small-cap biotechnology company with $100M in trailing revenue and exceptionally high gross margins (96.3%), suggesting a specialized therapeutic or diagnostic product portfolio. The company recently achieved profitability with 11.4% net margins and minimal debt (0.01 D/E), but faces revenue headwinds (-6.8% YoY) and negative free cash flow, indicating ongoing R&D investment or commercialization challenges. The stock trades at premium valuations (6.9x P/S, 46.7x EV/EBITDA) typical of biotech firms with pipeline optionality.
Gyre generates revenue through commercialized therapeutic products with minimal cost of goods sold (96.3% gross margin indicates high-value biologics or specialty pharmaceuticals with limited manufacturing costs). The business model relies on intellectual property protection, regulatory exclusivity, and specialized distribution channels. Pricing power derives from addressing unmet medical needs in niche therapeutic areas. The 15.3% operating margin suggests significant ongoing R&D and SG&A investment to support pipeline development and commercial infrastructure. Recent profitability achievement (113% net income growth) indicates operational inflection, though negative cash flow suggests working capital dynamics or non-cash accounting benefits.
Clinical trial data readouts and FDA regulatory milestones for pipeline candidates
Quarterly prescription volume trends and market share dynamics for commercialized products
Partnership announcements, licensing deals, or M&A speculation given $700M market cap
Reimbursement decisions from Medicare/Medicaid and private payers affecting product access
Competitive threats from biosimilars, generic entrants, or superior mechanism-of-action drugs
Regulatory pathway changes or heightened FDA scrutiny increasing approval timelines and development costs
Medicare drug price negotiation expansion under IRA legislation potentially compressing realized pricing for commercialized products
Patent cliff exposure if key product exclusivity expires without pipeline replacement, given concentrated revenue base
Reimbursement pressure from PBMs and payers demanding greater real-world evidence and cost-effectiveness data
Larger pharmaceutical companies developing competing mechanisms or superior efficacy profiles in same therapeutic areas
Biosimilar competition eroding market share and pricing power if products lack strong differentiation
Academic research or venture-backed startups advancing novel modalities (gene therapy, cell therapy) that obsolete current approaches
Negative free cash flow ($-0.0B) requiring future equity or debt financing, risking dilution at unfavorable valuations
Revenue decline (-6.8% YoY) threatening cash runway and potentially forcing capital raise during market weakness
Limited financial flexibility at $700M market cap to absorb clinical trial failures or commercial setbacks
low - Pharmaceutical demand is largely non-discretionary and driven by disease prevalence rather than economic conditions. However, elective procedures or non-critical therapies may see modest utilization pressure during recessions. The 6.19x current ratio provides substantial liquidity buffer against economic volatility. Biotech valuations are more sensitive to risk appetite and growth stock multiples than underlying business fundamentals.
Rising interest rates negatively impact biotech valuations through higher discount rates applied to future cash flows, particularly for pre-profitable or early-commercial companies. The 46.7x EV/EBITDA multiple makes GYRE vulnerable to multiple compression as 10-year Treasury yields rise. However, minimal debt (0.01 D/E) eliminates refinancing risk. Higher rates also reduce speculative capital flows into high-risk biotech sectors, pressuring stock performance independent of operational results.
Minimal - The company maintains negligible debt and strong liquidity (6.19x current ratio), eliminating credit market dependence for operations. However, biotech sector financing conditions affect equity capital availability for future fundraising. Tightening credit spreads and risk-off sentiment reduce institutional appetite for small-cap biotech exposure, potentially limiting strategic options.
growth - The premium valuation multiples (6.9x P/S, 46.7x EV/EBITDA), recent profitability inflection (113% net income growth), and biotech sector positioning attract growth-oriented investors seeking pipeline optionality and commercial expansion. The -35.8% one-year return suggests prior momentum investors have exited, leaving value-oriented biotech specialists and long-term holders. Minimal dividend yield (implied by cash flow profile) eliminates income investor appeal.
high - Small-cap biotechnology stocks exhibit elevated volatility driven by binary clinical/regulatory events, sector rotation dynamics, and limited trading liquidity. The 3-month (+6.3%) vs 1-year (-35.8%) performance delta illustrates sharp directional swings. Negative free cash flow and revenue decline amplify downside risk during risk-off periods. Expect beta >1.5 relative to broader market.
